Trastuzumab Resistance: What Are We Offering to Breast Cancer Patients?

Resistance to Trastuzumab in Breast Cancer.

HER2 is a transmembrane oncoprotein encoded by the HER2/neu gene and is overexpressed in approximately 20 to 25% of invasive breast cancers. It can be therapeutically targeted by trastuzumab, a humanized IgG1 kappa light chain monoclonal antibody. Although trastuzumab is currently considered one of the most effective treatments in oncology, a significant number of patients with HER2-overexpress...

Trastuzumab-Resistance and Breast Cancer

Evolution of therapeutic monoclonal antibodies significantly benefited from the recombinant DNA technologies that are used to generate chimeric, humanized, and human versions of monoclonal antibody to reduce the problem of immunogenicity and neutralization, as well as from understanding mechanisms of action mediated by monoclonal antibodies (Nelson et al., 2010; Reichert, 2009; Ranson & Sliwkow...

Overcoming Trastuzumab Resistance in Breast Cancer

A targeted therapy using the antibodies Trastuzumab (Genentech, CA) developed to block HER2 signaling has been successfully used to treat patients with metastatic breast cancers that overexpress HER2. However, resistance to trastuzumab therapy is a major obstacle in the clinical management of HER2+ breast cancer. Studies have suggested an interesting association between the mechanism of resista...

CCR FOCUS Resistance to Trastuzumab in Breast Cancer

HER2 is a transmembrane oncoprotein encoded by the HER2/neu gene and is overex-

Breast cancer diagnosis: what are we waiting for?